Fanconi Anemia - Pipeline Review, H2, Pharmaceutical 2016
"Fanconi
Anemia - Pipeline Review, H2 2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Fanconi Anemia - Pipeline Review, H2 2016, provides an
overview of the Fanconi Anemia (Hematological Disorders) pipeline
landscape.
Fanconi
anemia (fan-KO-nee uh-NEE-me-uh), or FA, is a rare, inherited blood
disorder that leads to bone marrow failure. The disorder also is
called Fanconis anemia. FA is a type of aplastic anemia. In aplastic
anemia, the bone marrow stops making or doesn't make enough of all
three types of blood cells. Low levels of the three types of blood
cells can harm many of the body's organs, tissues, and systems.
Treatment is recommended for significant cytopenias, such as
hemoglobin less than 8 g/dL, platelets fewer than 500/L.
Report
Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Fanconi Anemia - Pipeline Review, H2 2016, provides comprehensive
information on the therapeutics under development for Fanconi Anemia
(Hematological Disorders), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The
Fanconi Anemia (Hematological Disorders) pipeline guide also reviews
of key players involved in therapeutic development for Fanconi Anemia
and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase II, Phase
I, Preclinical and Discovery stages are 2, 1, 2 and 1 respectively.
Similarly, the Universities portfolio in Phase II, Phase I and
Preclinical stages comprises 1, 1 and 3 molecules,
respectively.Fanconi Anemia.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Fanconi Anemia (Hematological Disorders).
-
The pipeline guide reviews pipeline therapeutics for Fanconi Anemia
(Hematological Disorders) by companies and universities/research
institutes based on information derived from company and
industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Fanconi Anemia
(Hematological Disorders) therapeutics and enlists all their major
and minor projects.
-
The pipeline guide evaluates Fanconi Anemia (Hematological Disorders)
therapeutics based on mechanism of action (MoA), drug target, route
of administration (RoA) and molecule type.
Reasons
to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Fanconi Anemia (Hematological Disorders).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Fanconi Anemia (Hematological Disorders) pipeline depth and focus of
Indication therapeutics.
Comments
Post a Comment